The purpose of this study is to assess the effectiveness of Abatacept in real-world clinical practice. The main hypothesis to be examined in this study is, "Abatacept's effectiveness results in a single real-world clinic (n = 100) are reproducible at another site (n \~= 200)".
Two secondary hypotheses that will be tested are: * Abatacept aids in achieving low disease activity or clinical remission in patients of the following Rheumatoid Arthritis (RA) sub-groups: RF+/CCP+, RF+/CCP- RF-/CCP+ RF-/CCP-; first time on a bio-tech drug; having previously failed a biological drug; having interstitial lung disease; identified as disabled; twenty-eight individual joints identified as {swollen, painful, tender, deformed or having decreased range of motion}; on or not on oral DMARD; age; or gender. * A database with sufficient attributes exists from which a patient's efficacy on abatacept is accurately predictable.
Study Type
OBSERVATIONAL
Enrollment
200
As prescribed by a doctor for patient medical care.
Arthritis Northwest
Spokane, Washington, United States
Determine the efficacy of abatacept by analyzing the change in CDAI, DAS28, and RAPID3 scores.
Time frame: Change from baseline in CDAI, DAS28, and RAPID3 scores at approximately 6 months.
Determine the efficacy of abatacept by analyzing the change in CDAI, DAS28, and RAPID3 scores.
Time frame: Change from baseline in CDAI, DAS28, and RAPID3 scores at approximately 3 months.
Determine the efficacy of abatacept by analyzing the change in CDAI, DAS28, and RAPID3 scores.
Time frame: Change from baseline in CDAI, DAS28, and RAPID3 scores at approximately 9 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.